Urokinase Plasminogen Activator Receptor-PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand

PET Clin. 2017 Jul;12(3):311-319. doi: 10.1016/j.cpet.2017.02.003. Epub 2017 Apr 8.

Abstract

Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

Keywords: Breast cancer; Invasiveness; Molecular imaging; Oncology; PET; Prognostication; Prostate cancer; Theranostics.

Publication types

  • Review

MeSH terms

  • Gallium Radioisotopes*
  • Humans
  • Ligands*
  • Neoplasms / chemistry*
  • Neoplasms / diagnostic imaging*
  • Positron-Emission Tomography
  • Radionuclide Imaging / methods
  • Radiopharmaceuticals
  • Receptors, Urokinase Plasminogen Activator / analysis*
  • Tomography, X-Ray Computed

Substances

  • Gallium Radioisotopes
  • Ligands
  • Radiopharmaceuticals
  • Receptors, Urokinase Plasminogen Activator